# Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe Disease

> **NCT00074932** · NA · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 9 (actual)

## Conditions studied

- Glycogen Storage Disease Type II
- Glycogenosis 2

## Interventions

- **BIOLOGICAL:** Myozyme

## Key facts

- **NCT ID:** NCT00074932
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2006-08
- **Final completion:** 2006-12
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2014-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00074932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00074932, "Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe Disease". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00074932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*